Based on these findings, we performed preliminary in vivo experiments, evaluating the combination of GC1118 and the dual PI3K/mTOR inhibitor BEZ-235 [27], in a relatively GC1118-resistant CRC-024T model (KRASG12D showing high basal AKT activity (Figure 5). Here, MTOR is linked to colorectal carcinoma.